Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of switching from branded to generic antiretrovirals in virologically suppressed HIV-infected patients.
Gianotti N, Poli A, Galli L, Franzin M, Tadini P, Galizzi N, Carbone A, Merli M, Muccini C, Oltolini C, Andolina A, Spagnuolo V, Lazzarin A, Castagna A. Gianotti N, et al. Among authors: galizzi n. PLoS One. 2017 Aug 1;12(8):e0182007. doi: 10.1371/journal.pone.0182007. eCollection 2017. PLoS One. 2017. PMID: 28763473 Free PMC article.
Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients.
Gianotti N, Poli A, Nozza S, Galli L, Galizzi N, Ripa M, Merli M, Carbone A, Spagnuolo V, Lazzarin A, Castagna A. Gianotti N, et al. Among authors: galizzi n. BMC Infect Dis. 2017 Nov 16;17(1):723. doi: 10.1186/s12879-017-2831-9. BMC Infect Dis. 2017. PMID: 29145807 Free PMC article.
Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients.
Galizzi N, Poli A, Galli L, Muccini C, Mastrangelo A, Dell'Acqua R, Maillard M, Bossolasco S, Cinque P, Lazzarin A, Castagna A, Gianotti N. Galizzi N, et al. Int J Antimicrob Agents. 2020 Mar;55(3):105893. doi: 10.1016/j.ijantimicag.2020.105893. Epub 2020 Jan 9. Int J Antimicrob Agents. 2020. PMID: 31926287
Simplification to a dual regimen with darunavir/ritonavir plus lamivudine or emtricitabine in virologically-suppressed HIV-infected patients.
Fabbiani M, Di Giambenedetto S, Poli A, Borghetti A, Castagna A, Mondi A, Galizzi N, Maillard M, Gori A, Cauda R, De Luca A, Gianotti N. Fabbiani M, et al. Among authors: galizzi n. J Infect. 2016 Dec;73(6):619-623. doi: 10.1016/j.jinf.2016.08.011. Epub 2016 Aug 26. J Infect. 2016. PMID: 27575581 No abstract available.
An observational, retrospective analysis evaluating switching to raltegravir plus abacavir/lamivudine in HIV-1-infected patients: the ORASWIRAL study.
Galli L, Poli A, Muccini C, Galizzi N, Danise A, Spagnuolo V, Gianotti N, Carini E, Lazzarin A, Castagna A. Galli L, et al. Among authors: galizzi n. Infect Dis (Lond). 2018 Mar;50(3):220-222. doi: 10.1080/23744235.2017.1374552. Epub 2017 Sep 11. Infect Dis (Lond). 2018. PMID: 28891371 No abstract available.
15 results